ATE89547T1 - Dopamin-vorlaeufer. - Google Patents

Dopamin-vorlaeufer.

Info

Publication number
ATE89547T1
ATE89547T1 AT89114012T AT89114012T ATE89547T1 AT E89547 T1 ATE89547 T1 AT E89547T1 AT 89114012 T AT89114012 T AT 89114012T AT 89114012 T AT89114012 T AT 89114012T AT E89547 T1 ATE89547 T1 AT E89547T1
Authority
AT
Austria
Prior art keywords
compounds
formula
dopamine precursors
parkinson
hypertension
Prior art date
Application number
AT89114012T
Other languages
English (en)
Inventor
Cesare Casagrande
Francesco Santangelo
Original Assignee
Zambon Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zambon Spa filed Critical Zambon Spa
Application granted granted Critical
Publication of ATE89547T1 publication Critical patent/ATE89547T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT89114012T 1988-07-29 1989-07-28 Dopamin-vorlaeufer. ATE89547T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT8821543A IT1226727B (it) 1988-07-29 1988-07-29 Farmaci precursori della dopamina.
EP89114012A EP0352815B1 (de) 1988-07-29 1989-07-28 Dopamin-Vorläufer

Publications (1)

Publication Number Publication Date
ATE89547T1 true ATE89547T1 (de) 1993-06-15

Family

ID=11183351

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89114012T ATE89547T1 (de) 1988-07-29 1989-07-28 Dopamin-vorlaeufer.

Country Status (7)

Country Link
US (1) US5013753A (de)
EP (1) EP0352815B1 (de)
JP (1) JPH0296556A (de)
AT (1) ATE89547T1 (de)
DE (1) DE68906609T2 (de)
ES (1) ES2054949T3 (de)
IT (1) IT1226727B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001724A1 (en) * 1989-07-27 1991-02-21 G.D. Searle & Co. Renal-selective prodrugs for the treatment of hypertension
ATE248835T1 (de) * 1999-06-25 2003-09-15 Vertex Pharma Prodrugs von impdh-inhibierenden carbamaten
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
UA88792C2 (ru) * 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
DE102005022276A1 (de) * 2005-05-13 2006-11-16 Ellneuroxx Ltd. Derivate von Dihydroxyphenylalanin
US8017785B2 (en) * 2006-05-09 2011-09-13 Astrazeneca Ab Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine
TWI389889B (zh) * 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
WO2008091588A1 (en) * 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
GB0713189D0 (en) * 2007-07-06 2007-08-15 Proximagen Ltd Amino acid derivatives
ES2322121B1 (es) * 2007-12-10 2010-04-19 Consejo Superior De Investigaciones Cientificas Nuevos derivados de aminoacidos dicarboxilicos y su aplicacion en el tratamiento de enfermedades neurodegenerativas.
CN103180277A (zh) 2010-05-20 2013-06-26 塔格塞普特股份有限公司 制备芳基取代的烯属胺的新方法
CN112521305B (zh) 2013-03-15 2023-04-25 苏州泰飞尔医药有限公司 治疗帕金森疾病的新型高穿透力药物及其药物组合物
RU2021103000A (ru) 2014-10-21 2021-03-01 Эббви Инк. Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона
CR20200225A (es) 2017-11-24 2020-07-25 H Lundbeck As Nuevos fármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
JP6596483B2 (ja) * 2017-12-28 2019-10-23 テックフィールズ ファーマ カンパニー リミテッド パ−キンソン病治療用の新規高透過薬物及びその組成物
BR112021009353A2 (pt) 2018-11-15 2021-11-23 Abbvie Inc Formulações farmacêuticas para administração subcutânea
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
JP7641234B2 (ja) 2019-05-21 2025-03-06 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
EP3972971A1 (de) 2019-05-21 2022-03-30 H. Lundbeck A/S Neue catecholamin-prodrugs zur verwendung in der behandlung von morbus parkinson
WO2020234277A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease
WO2020234276A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3947590A (en) * 1973-10-23 1976-03-30 Abbott Laboratories Compositions and methods of increasing renal blood flow with gamma-glutamyl amide of dopamine
US3891696A (en) * 1973-11-02 1975-06-24 Interx Research Corp Novel, transient pro-drug forms of l-dopa
US4035507A (en) * 1975-04-17 1977-07-12 Interx Research Corporation Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease
US4031242A (en) * 1975-09-11 1977-06-21 Abbott Laboratories Diacylated derivatives of γ-glutamyl dopamine
US4125626A (en) * 1977-01-17 1978-11-14 Mt. Sinai School Of Medicine Of The City University Of New York Synthesis and use of L-γ-glutamyl-DOPA

Also Published As

Publication number Publication date
EP0352815A1 (de) 1990-01-31
DE68906609D1 (de) 1993-06-24
DE68906609T2 (de) 1993-08-26
EP0352815B1 (de) 1993-05-19
IT8821543A0 (it) 1988-07-29
IT1226727B (it) 1991-02-05
JPH0296556A (ja) 1990-04-09
ES2054949T3 (es) 1994-08-16
US5013753A (en) 1991-05-07

Similar Documents

Publication Publication Date Title
ATE89547T1 (de) Dopamin-vorlaeufer.
FI872864A0 (fi) Menetelmä farmaseuttisesti aktiivisten bentsimidatsolijohdannaisten valmistamiseksi
ES2070994T3 (es) Profarmaco de dopamina.
SE8804629D0 (sv) New therapeutically active compounds
EP0303697A4 (de) Derivate des physiologisch aktiven mittels k-252.
MX9203417A (es) Compuestos de diarilo antiateroescleroticos.
IT1228288B (it) Composti ad attivita' antiserotoninica
DE3882679D1 (de) Kardiovaskulaer aktive verbindungen.
ES2111352T3 (es) Uso de diester fosfato para el tratamiento de enfermedades retinianas.
EG19302A (en) Compound with gastric acid inhibitory effect and process for its preparation
SE8600658D0 (sv) Novel composition of matter
MA21026A1 (fr) Derives de 4-(aroylamino) piperidinebutanamide, et leur procede de preparation
DE69402004D1 (de) Beta-mercapto-propanamidderivate verwendbar zur Behandlung kardiovaskularer Krankheiten oder Erkrankungen
IT1216104B (it) Peptidi ad attivita' farmaceutica.
DK0420224T3 (da) Anthihepatopatisk middel
ATE88176T1 (de) 2-hydroxy-3-aryloxy-propylaminderivate mit kardiovaskulaerer wirkung.
IT1241927B (it) 3'-deamino-4'-deossi-4'-amino-8-fluoroantra- cicline processi per la loro preparazione e composizioni farmaceutiche che le contengono
ATE92037T1 (de) Kardiovaskulaer aktive verbindungen.
IT1216103B (it) Peptidi ad attivita' farmaceutica.
ATE81466T1 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur prophylaxe und zur behandlung von herzinsuffizienz.
GR3002708T3 (en) 4-(3-coumarinyl)-thiazole-derivatives with anti-allergic, anti-anaphylactic and anti-arthritic activity and compositions containing them
IT1204959B (it) Composti dotati di attivita' antiallergica
DK460789A (da) 2-aminoacetamidderivater
RU92016559A (ru) Производные диалкокси-пиридинилбензимидазола, фармацевтическая композиция, способ ингибирования или лечения, способ их получения, применение и промежуточные соединения
JO1664B1 (en) The compound has the effect of immobilizing gastric acid and the process of preparing it

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee